Evidence map›Paper›PMID 29961009›Full record

SynthesisBMJ open2018

A systematic review of epigenetic biomarkers in progression from non-dysplastic Barrett's oesophagus to oesophageal adenocarcinoma.

Tom Nieto, Claire L Tomlinson, Janine Dretzke, Susan Bayliss, Malcolm James Price, Mark Dilworth, Andrew D Beggs, Olga Tucker

Abstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in BMJ open, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Tom NietoDepartment of Surgery, University of Birmingham, Birmingham, UK.ORCID 0000-0002-7280-9138
Claire L TomlinsonBirmingham Clinical Trials Unit, Institute of Applied Health Research, University of Birmingham, Birmingham, UK.
Janine DretzkeInstitute of Applied Health Research, University of Birmingham, Birmingham, UK.
Susan BaylissInstitute of Applied Health Research, University of Birmingham, Birmingham, UK.
Malcolm James PriceInstitute of Applied Health Research, University of Birmingham, Birmingham, UK.
Mark DilworthDepartment of Surgery, Heart of England Foundation Trust and Institute of Inflammation and Ageing, University of Birmingham, Birmingham, UK.
Andrew D BeggsDepartment of Surgery, University of Birmingham, Birmingham, UK.
Olga TuckerDepartment of Surgery, University of Birmingham, Birmingham, UK.

Funding

Cancer Research UK 24430Medical Research Council MR/M009157/1
6 · The paper itself

Abstract

objectivesThe objective of this systematic review is to identify and summarise studies which examine epigenetic biomarkers in patients with Barrett's oesophagus (BO) and their association with progression to oesophageal adenocarcinoma (OADC). BO is a precursor lesion for OADC. There is no clinical test to predict patients who are likely to progress to OADC. An epigenetic biomarker could predict patients who are at high risk of progression from BO to OADC which could facilitate earlier diagnosis and spare those unlikely to develop cancer from regular invasive surveillance endoscopy.

settingA systematic search was conducted of the following databases: MEDLINE, MEDLINE in Process, EMBASE, Cochrane Central, ISI Conference Proceedings Citation Index and the British Library's ZETOC. Studies were conducted in secondary and tertiary care settings.

participantsAll studies measuring epigenetic change in patients over 18 years old who progressed from non-dysplastic BO to OADC were included. Genetic, in vitro and studies which did not measure progression in the same patient cohort were excluded. Study inclusion and risk of bias of individual eligible studies were assessed in duplicate by two reviewers using a modified Quality in Prognostic Studies tool.

results14 studies met the inclusion criteria. 42 epigenetic markers were identified, and 5 studies developed models aiming to predict progression to OADC.

conclusionsThe evidence from this systematic review is suggestive of a role for p16 as an epigenetic biomarker for the progression of BO to OADC. PROSPERO NUMBER: CRD42016038654.

Indexed as

Epigenesis, GeneticAdenocarcinomaBarrett EsophagusBiomarkers, TumorDisease ProgressionEndoscopyEsophageal NeoplasmsGastroesophageal RefluxHumansPrecancerous ConditionsPrognosisBiomarkers, Tumoradult surgerygastrointestinal tumoursoesophageal disease

Identifiers

PMID29961009
PMCPMC6042533

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.